One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1016/s2152-2650(21)02101-7
Copy DOI
Export
Save
Share
Cite Publication Date: Oct 1, 2021 | |
 Citations: 10 |
Affiliation: The University of Texas Southwestern Medical Center, Southwestern Medical Center, University Medical Center Hamburg-Eppendorf, Universität Hamburg, Massachusetts General Hospital, Bluebird Bio (France), University Hospital Würzburg, Dana-Farber Cancer Institute, VA Boston Healthcare System, Bristol-Myers Squibb (Germany), University of California System, University of California, San Francisco, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg University, Ospedale Papa Giovanni XXIII, University of Bologna, Istituto di Ematologia di Bologna, Tennessee Oncology, Sarah Cannon, Princess Margaret Cancer Centre, Centro de Investigación Biomédica en Red de Cáncer, Clinica Universidad de Navarra, Institut Català d'Oncologia
OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
